COX-2 Cardio Risk Is Class Effect, But Varies By Drug And Dose, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
While a COX-2 class signal is likely, several committee members suggest data are not conclusive enough to make a "global" statement on the class. Voting FDA consultant Nissen recommends FDA explore whether COX-2 inhibition plays a role in hypertension, thereby contributing to an increased cardiovascular risk.